Robot model
SAPIEN 3 Transcatheter Heart Valve
The SAPIEN 3 is a transcatheter aortic heart valve system used for TAVR (transcatheter aortic valve replacement) to treat severe aortic stenosis without…
- Manufacturer
- Edwards Lifesciences
- Form factor
- surgical
- Maturity
- production
- Lifecycle
- active
- Deployments
- 3
The verified answer
As of Aug 2026, DEPLOY verifies SAPIEN 3 Transcatheter Heart Valve, a surgical by Edwards Lifesciences (production): 3 verified deployments on record. 1 source back the record.
Overview
The SAPIEN 3 is a transcatheter aortic heart valve system used for TAVR (transcatheter aortic valve replacement) to treat severe aortic stenosis without open-heart surgery. FDA-approved for low-risk patients since August 2019, and approved for asymptomatic patients in May 2025. Includes SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA variants.
Verified vs. claimed
- Maturity stage
- production(Full-scale production deployment with repeat customers.)
- Sources on file
- View all sources →
Key facts
S&P 500 Component
Key Product
Manufacturing
Data & sources
Web sources
1
1 source backing this record.View all →
Pricing
No verified price is on record for SAPIEN 3 Transcatheter Heart Valve. Physical-AI systems are often sold through enterprise contracts or operated as a service rather than at a public list price.
Deployments (3)
Cedars-Sinai Medical Center, Los Angeles, is listed as a site in real-world SAPIEN 3 Ultra experience studies.
Cleveland Clinic TAVR operators began using a novel high deployment technique for SAPIEN 3 valve implantation in April 2017 to reduce conduction abnormalities and pacemaker requirements.
St.
SAPIEN 3 Transcatheter Heart Valve on the deployment map
View the global mapWhere SAPIEN 3 Transcatheter Heart Valve is verified operating. Explore the deployment map by place and type.
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Record createdJul 7, 2026
Added to the verified registry
- Incident recordedMay 16, 2025
FDA Class I recall of Edwards Lifesciences arterial cannulae due to risk of wire exposure
- Deployment verifiedVerifiedJan 1, 2019
at Los Angeles, California, USA
- Deployment verifiedVerifiedApr 1, 2017
at Cleveland, Ohio, USA
- Deployment verifiedVerifiedJan 1, 2013
at Vancouver, British Columbia, Canada
Safety record
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Incidents affecting SAPIEN 3 Transcatheter Heart Valve (1)
Includes incidents linked directly to this model or to deployments of it. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.
Sources (1)
Common questions
What is SAPIEN 3 Transcatheter Heart Valve?
How much does SAPIEN 3 Transcatheter Heart Valve cost?
Is SAPIEN 3 Transcatheter Heart Valve actually deployed in the real world?
Who makes SAPIEN 3 Transcatheter Heart Valve?
Where is SAPIEN 3 Transcatheter Heart Valve deployed?
Can you buy SAPIEN 3 Transcatheter Heart Valve?
What are alternatives to SAPIEN 3 Transcatheter Heart Valve?
How does SAPIEN 3 Transcatheter Heart Valve compare to Edge Multi-Port Surgical Robot?
Is SAPIEN 3 Transcatheter Heart Valve a top surgical?
What is SAPIEN 3 Transcatheter Heart Valve's maturity stage?
Is SAPIEN 3 Transcatheter Heart Valve safe?
Methodology: Verified · 1 source (no primary) · last reviewed 2026-07-12
Verification posture
Verified
Low confidence
Review state
Stable
Last reviewed 2026-07-12
Maturity + lifecycle
Maturity stage: production
Lifecycle: active
Architectural position
Cohort: surgical
Sources by quality tier
- 1
- knowledge-base
- Knowledge base
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for SAPIEN 3 Transcatheter Heart Valve.Recent coverage
SAPIEN 3 Transcatheter Heart Valve in third-party press
Attention vs reality over time
Media mentions per month (area) against verified deployment events (dots). A press spike over a flat deployment line is the hype gap, drawn over time.
In the press
Recent coverage mentioning SAPIEN 3 Transcatheter Heart Valve from third-party publications. Automatically surfaced; not part of the verified registry record.
CMS Proposes TAVR Medicare Coverage is Potential Boost for Edwards Lifesciences
CMS’s proposed expansion of Medicare TAVR coverage to include select asymptomatic severe aortic stenosis patients and reduce access barriers for symptomatic patients could…
FTC Challenges Anticompetitive Medical Device Deal
The FTC challenged Edwards Lifesciences' acquisition of JenaValve, alleging it would disrupt competition for revolutionary heart condition devices.
FDA: Edwards Lifesciences Removes Arterial Cannula due to Risk of Wire Exposure
FDA issued a Class I recall for Edwards Lifesciences OptiSite Arterial Perfusion Cannula and Peripheral Femoral Arterial Cannula models due to risk of wire exposure that could…
Edwards Lifesciences Reports Fourth Quarter Results
Edwards Lifesciences reported Q4 and full-year 2025 financial results, with revenue of US.07 billion.
Edwards Lifesciences chair Michael Mussallem retires from board
Michael Mussallem retired from the Edwards Lifesciences board after 23 years as CEO and chair, having led the company since its 2000 IPO spin-off from Baxter.
Machine-readable surfaces
- Markdown mirror: /models/sapien-3-transcatheter-heart-valve.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/models/11d93de0-ecbc-40c1-9cbf-78faec650556
- Revision history: /models/sapien-3-transcatheter-heart-valve/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Video
How the EVOQUE valve is implanted via the transfemoral approach: A step-by-step illustration of tricuspid valve replacement with the EVOQUE Tricuspid Valve Replacement System. Content related to Edwards Lifesciences de
In 1958, Miles “Lowell” Edwards set out to build an artificial heart. But like so many other great inventors, Edwards and his trusted partner, Dr. Albert Starr,
Cutting-edge medical science helped Edwards Lifesciences' stock stay healthy so far in 2017, with a rise of over 25% year to date. Could it continue to head hig
Edwards Lifesciences CEO Michael Mussallem tells CNBC's Jim Cramer that the medical equipment company has prioritized improving care for structural heart diseas
Discover the challenges and requirements for the effective treatment of tricuspid valve disease. A global panel of experts draws upon multi-centre, real-world e
Driven by a passion to help, Edwards Lifesciences collaborates with the world’s leading clinicians and researchers, working to improve outcomes and enhance live
There are many different pathways students can take to be involved in medical innovation and entrepreneurship. Hear from a variety of industry professionals as
In this episode, Gary speaks with Michael A. Mussallem, Chairman and CEO, Edwards Lifesciences. They spoke about the future of healthcare technology and innovat
Rick, a farmer from Canada, has been hardworking his entire life. As a child, he was sick with rheumatic fever, which left his heart valves damaged and caused h
Reality vs attention
SAPIEN 3 Transcatheter Heart Valve draws attention at the 75th percentile but verifies reality at the 68th percentile among surgical robots. Hype Gap +6.1, 17th widest among surgical robots.
6-month trend
Analysis
Thin deployment record; scale validation still in progress.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Aug 24, 2026